

Interim Analysis Report of Anti SARS Cov 2 antibodies among vaccinated healthcare providers in VIMSAR, Burla

Investigators:

1. Dr Sanjeeb Kumar Mishra, Senior Resident, Dept. of Community Medicine, VIMSAR
2. Dr Subrat Kumar Pradhan, Associate Professor, Dept. of Community Medicine, VIMSAR
3. Dr. Sanghamitra Pati, Director, RMRC, Bhubaneswar
4. Dr. Bimal Krushna Panda, Nodal officer, MDRU, VIMSAR

Methods – This is a part of the ongoing repeated cross-sectional study. Participants were enrolled well above the Sample size (322) to increase precision. Two rounds of survey have been completed & are being reported. The samples were transported maintaining a cold chain (2-8°C) to the serology laboratory at ICMR-Regional Medical Research Centre in Bhubaneswar for antibody testing and analysis.

Antibodies against spike protein of SARS-CoV-2 was estimated using Elecsys® Anti-SARS-CoV-2S is an immunoassay by ECLIA based Cobas e411 analyzer. Univariate and multivariate regression were used in statistical analysis.

Results - Our results show 95.1 % and 99.5% of the vaccinated individuals have developed anti spike protein antibodies after the 1st and 2nd dose respectively. Previous Covid infection was significantly correlated with antibody production and age was negatively correlated. No difference was reported for sex, occupation, diabetes.

Conclusion. Our interim analysis report is coherent with the available literature and research regarding high efficacy of Covid vaccine as far as seroconversion is concerned.